Rapport Therapeutics Inc Dossier - Source-backed chat

Rapport Therapeutics Inc

RAPPNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.02

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $32.83Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.6B

Enterprise Value $1.5B

Shares Outstanding 50.9M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Rapport Therapeutics is a high-potential, clinical-stage biotechnology company leveraging its proprietary Receptor Associated Protein (RAP) platform to develop highly localized, precision neuromedicines. The company's lead candidate, RAP-219, targets TARPγ8-specific AMPA receptors, offering a highly differentiated safety and efficacy profile compared to traditional anti-seizure medications. Backed by robust Phase 2a follow-up data showing sustained seizure reduction, Rapport is transitioning into a pivotal Phase 3 development stage for focal onset seizures (FOS) in Q2 2026. A strategic $328 million licensing deal with Tenacia Biotechnology for Greater China provides non-dilutive capital and global validation. With a robust cash balance of $476.8 million extending its runway into the second half of 2029, Rapport is well-positioned to achieve multiple late-stage clinical milestones without near-term financing risk.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$50.00

Mean target$62.05

High · most bullish analyst$80.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$50.00

The bear case is triggered by clinical setbacks, such as safety concerns or a lack of efficacy in the Phase 2 bipolar mania readout in Q4 2026, or enrollment delays in the Phase 3 FOS trials. Additionally, intense competition from more advanced assets (such as Xenon's azetukalner) could compress RAP-219's ultimate market share, leading to a downward re-rating of the stock despite its strong cash position.

Base CaseCentral scenario

$62.05

Matches the consensus mean

The base case assumes successful initiation of the Phase 3 FOS program in Q2 2026 with steady enrollment. The Phase 2 bipolar mania trial in Q4 2026 meets its primary endpoints, demonstrating clinical signal but requiring further optimization. The cash runway remains secure into 2029, allowing the company to advance its preclinical pipeline (including chronic pain and hearing disorders) while maintaining steady progress toward FOS registration.

Bull CaseUpside scenario

$80.00

The bull case assumes RAP-219 successfully initiates and rapidly enrolls its Phase 3 FOCUS 1 and FOCUS 2 trials in FOS, while the Phase 2 bipolar mania trial delivers positive topline results in Q4 2026. This would validate RAP-219's 'pipeline-in-a-product' potential across both neurological and psychiatric indications. Rapid clinical progress, combined with milestone payments from Tenacia and the advancement of the long-acting injectable formulation, would position Rapport as a prime acquisition target or a leading independent neurology franchise.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary RAP platform enables neuroanatomical specificity, minimizing off-target side effects common in traditional CNS drugs.
Strong Phase 2a follow-up data for RAP-219 in FOS, demonstrating a 90% median reduction in clinical seizures in weeks 9-12.
Robust balance sheet with $476.8 million in cash and short-term investments, providing a runway into H2 2029.
Strategic partnership with Tenacia Biotechnology for Greater China, yielding $20 million upfront and up to $308 million in milestones plus royalties.

Key Investment Risks

High clinical and regulatory risk inherent in late-stage CNS drug development.
Intense competition in the focal epilepsy space, particularly from Xenon Pharmaceuticals' azetukalner, which is further advanced in clinical development.
Binary risk associated with the upcoming Phase 2 bipolar mania topline readout in Q4 2026.

Thesis Invalidation Triggers

Failure of RAP-219 to meet primary endpoints in the Phase 3 FOS trials (FOCUS 1 and FOCUS 2).
Severe, unexpected adverse safety events emerging during the Phase 3 FOS trials or the Phase 2 bipolar mania trial.
Significant delays in Phase 3 trial enrollment that push back the expected regulatory filing timeline beyond 2028.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.